

REFERENCES

1. Gibaldi M, Perrier D. *Pharmacokinetics*. 2nd. New York: Marcel Dekker, 1982.
2. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. *Pharm Res* 1999; 16:176–185.
3. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. *Annu Rev Pharmacol Toxicol* 2000; 40:67–95.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. *Guidance For Industry: Exposure–Response Relationships: Study Design, Data Analysis, and Regulatory Applications*. April, 2003.
5. Colburn WA. Biomarkers in drug discovery and development: identification through drug marketing. *J Clin Pharmacol* 2003; 43:329–341.
6. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. *J Clin Pharmacol* 2000; 40:1419–1427.
7. Della Paschoa OE, Mandema JW, Voskuyl RA, Danhof M. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. *J Pharmacol Exp Ther* 1998; 284:460–466.
8. Cox EH, Kerbusch T, van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. *J Pharmacol Exp Ther* 1998; 284:1095–1103.
9. Cox EH, Langemeijer MW, Gubbens-Stibbe JM, Muir KT, Danhof M. The comparative pharmacodynamics of remifentanyl and its metabolite, GR90291, in a rat electroencephalographic model. *Anesthesiology* 1999; 90:535–544.
10. Parker TJ, Della Pasqua OE, Loizillon E, Cezaubernard C, Jochemsen R, Danhof M. Pharmacokinetic–pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924, and S 19327 in the EEG model in rats. *Br J Pharmacol* 2001; 132:151–158.
11. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. *J Pharmacol Exp Ther* 1999; 289:1067–1074.
12. Gomeni R, Falcoz C, D’Angeli C, Bye A. In-silico prediction of drug properties in man using preclinical data and computer-assisted drug development. *Drug Infor J* 2001; 35:1047–1063.
13. Gomeni R, Bani M, D’Angeli C, Corsi M, Bye A. Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. *Eur J Pharm Sci* 2001; 13:261–270.
14. Ferron GM, McKeand W, Mayer P. Pharmacodynamic modeling of pantoprazole’s irreversible effect on gastric acid secretion in humans and rats. *J Clin Pharmacol* 2001; 41:149–156.
15. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D et al. Use of preclinical data for selection of a phase II/III dose for evernimicin